# Effect of rhGM-CSF on the Healing of Venous Leg Ulcers

> **NCT04823962** · PHASE2 · UNKNOWN · sponsor: **Reponex Pharmaceuticals A/S** · enrollment: 6 (actual)

## Conditions studied

- Venous Leg Ulcer

## Interventions

- **DRUG:** rhGM-CSF + hydrogel
- **DRUG:** Placebo hydrogel
- **OTHER:** Standard care

## Key facts

- **NCT ID:** NCT04823962
- **Lead sponsor:** Reponex Pharmaceuticals A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-11
- **Primary completion:** 2023-12-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2022-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04823962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04823962, "Effect of rhGM-CSF on the Healing of Venous Leg Ulcers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04823962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*